Date updated:08-16-2008
With patents on some major products expiring over the next few years, large pharmaceutical companies will be on the prowl for biotech outfits with promising drugs.

-
ONXX
Onyx Pharmaceutic - $36.50
- +5.86%
- $34.85
Thapar and other analysts point to Onyx Pharmaceuticals (ONXX) as a potential target of Bayer. Onyx has a joint venture with the German pharmaceutical giant for Nexavar, which is used to treat kidney and liver cancers. "At some point, you could see Bayer wanting to control 100% of the assets," says Sustersic, who thinks that Bayer might pay as much as $65 per share. Nexavar is believed to have more upside, especially as it secures approval in other markets (it was recently given the green light by China as a liver-cancer treatment), and even more if it can be used for other cancers, including those of the breast, lungs and skin.

-
VRTX
Vertex Pharmaceut - $31.63
- -1.62%
- $32.21
Not all of the focus is on products already in the market, however. Vertex Pharmaceuticals (VRTX), another company that some investors view as an eventual takeover candidate, is developing Telaprevir, a substance that promises to reduce the time needed to treat hepatitis-C, a potentially fatal liver ailment. Telaprevir is currently in stage III testing, the last phase of the clinical- trial process. Vertex has worked with Johnson & Johnson (JNJ) in developing that drug.

-
AMLN
Amylin Pharmaceut - $12.15
- +6.39%
- $11.42
Another company that could spark an acquirer's interest is Amylin Pharmaceuticals (AMLN). It's working on a Type 2 diabetes drug that could be injected once a week instead of daily. Amylin has several development partners, including Eli Lilly, on the drug. It already markets two diabetes drugs, Symlin and Byetta. But some analysts say the product under development could boast major advantages. "A once-weekly drug that lowers glucose substantially, induces weight loss, isn't associated with hypoglycemia, and lacks a cardiovascular safety signal has multibillion-dollar potential," says Markowitz.

-
UTHR
United Therapeuti - $65.94
- +1.45%
- $65.51
Anyone scanning the biotech ranks for potential acquisition targets shouldn't overlook United Therapeutics (UTHR). It has one characteristic that lots of other small biotechs would envy: It's in the black. One of its most promising products is Remodulin, which is used to treat hypertension in the blood vessels of the lungs. Although there are other PAH drugs, Turner Investment Partners' Sustersic says that United Therapeutics is "one of the clear leaders, and they potentially could have a big blockbuster."

-
ALXN
Alexion Pharmaceu - $36.82
- -0.49%
- $37.33
American Century's Thapar is similarly impressed by Alexion Pharmaceuticals (ALXN), which earned six cents a share in its most recent quarter, versus a loss of 75 cents a share a year earlier. Its drugs include Soliris, which treats a rare disorder called paroxysmal nocturnal hemoglobinuria, which destroys red blood cells. At $389,000 a year per patient, Soliris is hugely expensive -- but it targets a clearly defined patient base. The drug had net sales of nearly $60 million in the second quarter, up from $45.5 million in the first quarter and $9.8 million a year earlier. Regulators have approved its use in the U.S. and Europe, and it's expected to be introduced in Japan toward the end of next year. Alexion retains distribution rights in the U.S. and overseas, says Sustersic, who maintains that Soliris sales could reach at least $500 million a year.
- Barron's Biotech Buyout Candidates's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Charlie Munger
- 2. Bernard L. Madoff Inve...
- 3. Renaissance Technologies
- 4. Templeton World A (TEMWX)
- 5. Fidelity Select Consum...
- show all
- Top Do-It-Yourself Portfolios
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » HMH1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » 10 Short Squeezes
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- show all
Investors were spooked on Wednesday as bleak broad-based corporate outlooks and dismal employment data dominated headlines. Stocks experienced their largest drop in more t...
At Stockpickr.com, we strive to keep track of insider purchasing and buybacks each week. Here's the perfect setup in my mind: insiders buying the stock, the company buying ...
The traders of CNBC’s "Fast Money" think the current stock market is a traders' market. In order to play a traders' market, you have to nimble. You also have to know whic...
Pfizer (PFE) CEO Jeff Kindler has hinted that the world’s biggest drugmaker is open to a large-scale acquisition. “The real goal is to grow revenues," he told the Fina...
A. agree with mike, if you are new to
investing the market the best think you
can do right now is watch. The market
is not cheap in any way right now other
than the comparsion of where it just was
over a year ago. The market and economy
are going to a lot longer than what most
people think to become stable let alone
recover.
A. small trading before thrusday
These stocks were upgraded by TheStreet.com Ratings on Dec. 29, 2008. more
Stocks with market capitalizations between $250 million and $1 billion with a P/E ratio less than or equal to 10 and a quick ratio of greater than or equal to 1.0. A quick ... more
Dow Jones Industrial Average stocks that have a yield of greater than or equal to 3. In the description box for each stock is its current yield. more






Comments not available